Abstract:Abstract Folate receptor α (FRα) is overexpressed in a range of solid tumors with limited expression in normal tissues, hence an attractive target for an antibody-drug conjugate (ADC). PRO1184 is comprised of a human monoclonal antibody that selectively binds FRα, a novel cleavable hydrophilic linker, and a topoisomerase 1 inhibitor payload, exatecan. Previous studies established that a) PRO1184 exerts potent antitumor activity in cell-derived xenograft (CDX) models representing ovarian, non-small cell lung, and breast cancer, b) with pharmacokinetics (PK) akin to that of the unconjugated parent antibody in rats, and c) with a preliminary safety profile that was more favorable than a DXd-based ADC in cynomolgus monkeys. Further characterization of the activity and safety of PRO1184 is reported here. PRO1184 displays strong binding affinity, rapid internalization, and potent cytotoxicity with the HCC1954 (breast cancer), JEG-3 (choriocarcinoma), and HEC-1-A (endometrial cancer) cells, in vitro. PRO1184 at a single dose of 5 mg/kg produced marked tumor growth inhibition in CDX models with all three cell lines. In 14 patient-derived xenograft (PDX) models encompassing ovarian, gastric, breast, and non-small cell lung cancer, PRO1184 at a single dose of 5 mg/kg elicited robust antitumor activity in all four tumor types, with ORR and CR accomplished in 10 and 3 out of the 14 models, respectively. Antitumor activity was observed in xenografts with both high and low FRα expression, suggesting that PRO1184 may benefit patients with a wide range of FRα expression. Two DM4-based benchmarking ADCs produced modest to negligible tumor growth inhibition in head-to-head comparisons in the CDX and PDX studies. In a GLP cynomolgus monkey toxicity study for PRO1184, main treatment-related findings were consistent with those associated with exatecan and included reversible gastrointestinal and hematologic toxicities. There were no toxicity findings in lungs, which may translate to a lower risk of interstitial lung disease (ILD) compared to DXd-based ADCs in the clinic. In summary, PRO1184 is a promising development candidate for the treatment of FRα-expressing solid tumors. A first in human phase 1/2 study in patients with advanced solid tumors is currently recruiting (NCT 05579366). Citation Format: Lei Wang, Haidong Liu, Chang Zhou, Tae Han, Baiteng Zhao, Zhu Chen. Novel folate receptor alpha-directed antibody-drug conjugate PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2637.

Development of a human viable heavy chain antibody against the alpha folate receptor as a molecule for targeted application by phage display technology

Abstract 2584: Development of an Fc gamma receptor fully-humanized mouse model to support the accurate preclinical study of therapeutic antibodies

Folate Receptor Alpha—A Novel Approach to Cancer Therapy

[Eukaryotic Expression and Determination of ZCH-7-2F9 Single Chain Antibody Against Human CD14].

Identification of a Peptide for Folate Receptor Alpha by Phage Display and Its Tumor Targeting Activity in Ovary Cancer Xenograft

Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2.

Development of a [89Zr]Zr-labeled human antibody using a novel phage-displayed human scFv library

The folate receptor as a rational therapeutic target for personalized cancer treatment

Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy

Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach

Identification and Characterization of Tumor Antigens by Using Antibody Phage Display and Intrabody Strategies

Generation and Characterization of a Novel Human IgG1 Antibody Against Vascular Endothelial Growth Factor Receptor 2

Screening and Preclinical Evaluation of Novel Radiolabeled Anti-Fibroblast Activation Protein- Recombinant Antibodies

Abstract 2637: Novel Folate Receptor Alpha-Directed Antibody-Drug Conjugate PRO1184 Demonstrates Broad Antitumor Activity with a Promising Safety Profile in Preclinical Models

Isolation and identification of single chain Fv antibodies against breast cancer from a human phage display library]

Progress of Targeted Therapy on the Cancer Mediated Mate Receptor

[Selection and Characterization of Human Antibodies Against Vascular Endothelial Growth Factor from Human Phage Display Antibody Library].

Abstract 5910: Developing a novel humanized anti-FABP4 antibody for breast cancer treatment

Screening and characterization of human anti-GPC3 single chain Fv antibody fragment selected by phage display

Phage‐derived Fully Human Antibody Scfv Fragment Directed Against Human Vascular Endothelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF

Isolation and characterization of a novel single-chain variable fragment (scFv) against Lymphocyte function-associated antigen-1 (LFA-1) using phage display method